Neuro-Oncology Outcomes Laboratory, Department of Neurosurgery, Johns Hopkins University, Baltimore, MD 21202, USA.
J Clin Neurosci. 2013 Jun;20(6):818-23. doi: 10.1016/j.jocn.2012.07.016. Epub 2013 Apr 29.
Patients with glioblastoma (GB) are known to have poor prognoses, and among these patients, those with poor neurological function have an even poorer prognosis. Consequently, aggressive surgeries and adjuvant therapies are often withheld because of this dismal outlook. The effects of aggressive therapies in this small subset of patients remain unknown. The goal of this study was to evaluate outcomes and factors associated with survival for poor functioning patients who underwent aggressive resection of their GB. Adult patients who underwent surgical resection of an intracranial primary GB at an academic tertiary-care institution between 1997 and 2007 were retrospectively reviewed. Patients with a Karnofsky Performance Scale (KPS) score of ≤60 were included. A total of 100 patients with primary GB met the inclusion criteria. The average age (± standard deviation) and KPS score of this cohort were 54 ± 15 years and 53 ± 12, respectively. No patient (0%) experienced perioperative mortality, and 0 (0%), 10 (10%), and 3 (3%) of patients incurred a new or increasing language, motor, and visual deficit, respectively. At last follow-up, 88 (88%) patients died with a median survival of 6.6 months. The factors associated with improved survival were age <65 year (p = 0.005), tumor size >2 cm (p = 0.01), radical tumor resection (p=0.01), and temozolomide (p = 0.001). This study identifies a subset of patients with poor functional status who may benefit from aggressive surgical resection.
患有胶质母细胞瘤(GB)的患者预后较差,而这些患者中,神经功能较差的患者预后更差。因此,由于这种悲观的前景,往往会放弃积极的手术和辅助治疗。在这一小部分患者中,积极治疗的效果仍不清楚。本研究的目的是评估功能不良患者接受积极切除 GB 后的结果和与生存相关的因素。
回顾性分析了 1997 年至 2007 年期间在学术性三级保健机构接受颅内原发性 GB 手术切除的成年患者。纳入 Karnofsky 表现量表(KPS)评分≤60 的患者。共有 100 名原发性 GB 患者符合纳入标准。该队列的平均年龄(±标准差)和 KPS 评分为 54±15 岁和 53±12。没有患者(0%)发生围手术期死亡,0(0%)、10(10%)和 3(3%)的患者分别出现新的或加重的语言、运动和视觉缺陷。在最后一次随访时,88(88%)名患者死亡,中位生存时间为 6.6 个月。与生存改善相关的因素包括年龄<65 岁(p=0.005)、肿瘤大小>2cm(p=0.01)、根治性肿瘤切除术(p=0.01)和替莫唑胺(p=0.001)。
本研究确定了一组功能状态较差的患者,他们可能受益于积极的手术切除。